Skip to main content
SpringerLink
Log in

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Recent diagnostic and cancer reporting changes influencing myeloproliferative neoplasms (MPNs) encourage the assessment of trends and examination of the recently identified MPN subtypes: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), across the age continuum by race and ethnicity.

Methods

Surveillance, Epidemiology, and End Results data provided MPN incidence data since 1973 and MPN subtype data since 2001. Joinpoint regression estimated annual percent changes. Poisson regression estimated risk ratios.

Results

The 2005 JAK2 V617F discovery and the 2008 WHO diagnostic guideline for the JAK2 V617F mutation coincide with a 31 % increase in ET and a 21 % decrease in PV incidence rates. We found that younger women had a 13–33 % higher ET risk and that women under the age of 34 had a 58 % higher PMF risk, relative to men. Blacks, aged 35–49 with a higher ET risk, also had a 69 % higher PMF risk relative to whites.

Conclusion

Demographic characteristic of ET and PMF patients may be useful for improving risk prediction and informing clinical screening and treatment strategies. Changing guidelines, new discoveries, and in-depth analysis of a large population-based study have implications for accurately identifying incident cases of MPNs, MPN subgroups, and health resource planning.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Alvarez-Larrán BB, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89:517–523

    Article  PubMed  Google Scholar 

  • Anderson LA, McMullin MF (2014) Epidemiology of MPN: what do we know. Curr Hematol Malig Rep 9:340–349

    Article  CAS  PubMed  Google Scholar 

  • Bain BJ (2004) The World Health Organization classification of myeloproliferative and myelodysplastic syndromes. Curr Diagn Pathol 10:394–403

    Article  Google Scholar 

  • Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R (2009) The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 9:252

    Article  PubMed Central  PubMed  Google Scholar 

  • Chasseriau J, Rivet J, Bilan F, Chomel J-C, Guilhot F, Bourmeyster N, Kitzis A (2004) Characterization of the different BCR–ABL transcripts with a single multiplex RT-PCR. J Mol Diagn 6:343–347

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Craig BM, Rollison DE, List AF, Cogle CR (2011) Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res 35:1453–1456

    Article  PubMed Central  PubMed  Google Scholar 

  • Craig BM, Rollison DE, List AF, Cogle CR (2012) Underreporting of myeloid malignancies by united states cancer registries. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 21:474–481

  • Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G (1983) Localization of the c-ABL oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 306:239–242

    Article  CAS  PubMed  Google Scholar 

  • Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G (1985) Structural organization of the BCR gene and its role in the Ph’ translocation. Nature 315:758–761

    Article  CAS  PubMed  Google Scholar 

  • James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434:1144–1148

    Article  CAS  PubMed  Google Scholar 

  • Joinpoint Regression Program, Version 4.1.1.4—February (2015) Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute

  • Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168

    Article  CAS  PubMed  Google Scholar 

  • Kim H, Fay MP, Yu B, Barrett MJ, Feuer EJ (2004) Comparability of segmented line regression models. Biometrics 60:1005–1014

    Article  PubMed  Google Scholar 

  • Kramárová E, Stiller CA (1996) The international classification of childhood cancer. Int J Cancer 68:759–765

    Article  PubMed  Google Scholar 

  • Kvasnicka HM (2013) WHO classification of myeloproliferative neoplasms (MPN): a critical update. Curr Hematol Malig Rep 8:333–341

    Article  PubMed  Google Scholar 

  • Ma X, Does M, Raza A, Mayne ST (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109:1536–1542

    Article  PubMed  Google Scholar 

  • NAACCR Race and Ethnicity Work Group (2014) NAACCR Guideline for enhancing hispanic/latino identification: revised NAACCR hispanic/latino identification algorithm[NHIA v2.2.1].Springfield (IL): North American Association of Central Cancer Registries

  • National Cancer Institute (2013) SEER (Surveillance, Epidemiology and End Results). http://seer.cancer.gov/registries/data.html. Accessed 15 December 2014

  • NCI. Cancer Trends Progress Report-2011/2012 Update (2012) National Cancer Institute, NIH, DHHS, Bethesda, MD http://progressreport.cancer.gov. Accessed 14 December 2014

  • Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 9(3):e90299

    Article  PubMed Central  PubMed  Google Scholar 

  • Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorder in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45–52

    Article  CAS  PubMed  Google Scholar 

  • SAS/STAT software, Version 9.3 of the SAS System for PC. (2014) SAS Institute Inc., Cary, NC, USA

  • SEER (2015) Fast stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. http://seer.cancer.gov/faststats. Accessed 10 March 2015

  • Selinger HA, Ma X (2009) Jakking up tumor registry reporting of the myeloproliferative neoplasms. Am J Hematol 84:124–126

    Article  PubMed  Google Scholar 

  • Spivak JL, Silver RT (2008) The revised WHO Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112:231–239

    Article  CAS  PubMed  Google Scholar 

  • Staerk J, Constantinescu SN (2012) The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAK-STAT 1:184–190

    Article  PubMed Central  PubMed  Google Scholar 

  • Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P (2005) International classification of childhood cancer, third edition. Cancer 103:1457–1467

    Article  PubMed  Google Scholar 

  • Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: incidence—SEER 9 Regs Research Data, Nov 2013 Sub (1973–2011) <Katrina/Rita Population Adjustment>- Linked To County Attributes—Total US, 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. www.seer.cancer.gov. Accessed 16 Sept 2014

  • Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA (2008) Cancer risk in patients with constitutional chromosome deletions: a nationwide British cohort study. Br J Cancer 98:1929–1933

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson Ch et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:1472–1477

    Article  CAS  PubMed  Google Scholar 

  • Titmarsh GL, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F et al (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 112:581–587

    Article  Google Scholar 

  • Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951

    Article  CAS  PubMed  Google Scholar 

  • Yacoub A, Odenike O, Verstovsek S (2014) Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep 9:350–359

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Zhang SP, Li H, Lai RS (2015) Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms. Oncol Lett 9:735–738

    PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors claim no conflict of interest.

Ethical standard

This research was declared exempt from the Office of Research Integrity at the University of Nevada, Reno.

Author information

Authors and Affiliations

  1. School of Community Health Sciences, University of Nevada, Mail Stop 274, 1664 North Virginia Street, Reno, NV, 89557, USA

    Melissa A. Deadmond & Julie A. Smith-Gagen

  2. Biology Department, Truckee Meadows Community College, Mail Stop SIER 200S, 7000 Dandini Boulevard, Reno, NV, 89512, USA

    Melissa A. Deadmond & Julie A. Smith-Gagen

Authors
  1. Melissa A. Deadmond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie A. Smith-Gagen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie A. Smith-Gagen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deadmond, M.A., Smith-Gagen, J.A. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011. J Cancer Res Clin Oncol 141, 2131–2138 (2015). https://doi.org/10.1007/s00432-015-1983-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-015-1983-5

Keywords

Search

Navigation